|
1
|
Quintás-Cardama A and Cortes J: Molecular
biology of bcr-abl1-positive chronic myeloid leukemia. Blood.
113:1619–1630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bixby D and Talpaz M: Seeking the causes
and solutions to imatinib-resistance in chronic myeloid leukemia.
Leukemia. 25:7–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ou J, Vergilio JA and Bagg A: Molecular
diagnosis and monitoring in the clinical management of patients
with chronic myelogenous leukemia treated with tyrosine kinase
inhibitors. Am J Hematol. 83:296–302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lemoli RM, Salvestrini V, Bianchi E,
Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R,
Testoni N, et al: Molecular and functional analysis of the stem
cell compartment of chronic myelogenous leukemia reveals the
presence of a CD34− cell population with intrinsic
resistance to imatinib. Blood. 114:5191–5200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johansson B, Fioretos T and Mitelman F:
Cytogenetic and molecular genetic evolution of chronic myeloid
leukemia. Acta Haematol. 107:76–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jamieson CH, Ailles LE, Dylla SJ,
Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating
A, et al: Granulocyte-macrophage progenitors as candidate leukemic
stem cells in blast-crisis CML. N Engl J Med. 351:657–667. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giehl M, Fabarius A, Frank O, Hochhaus A,
Hafner M, Hehlmann R and Seifarth W: Centrosome aberrations in
chronic myeloid leukemia correlate with stage of disease and
chromosomal instability. Leukemia. 19:1192–1197. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmitt M, Li L, Giannopoulos K, Chen J,
Brunner C, Barth T, Schmitt A, Wiesneth M, Döhner K, Döhner H, et
al: Chronic myeloid leukemia cells express tumor-associated
antigens eliciting specific CD8+ T-cell responses and
are lacking costimulatory molecules. Exp Hematol. 34:1709–1719.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greiner J, Ringhoffer M, Taniguchi M,
Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L,
Döhner H, et al: Receptor for hyaluronan acid-mediated motility
(RHAMM) is a new immunogenic leukemia-associated antigen in acute
and chronic myeloid leukemia. Exp Hematol. 30:1029–1035. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giannopoulos K, Dmoszynska A, Kowal M,
Rolinski J, Gostick E, Price DA, Greiner J, Rojewski M,
Stilgenbauer S, Döhner H, et al: Peptide vaccination elicits
leukemia-associated antigen-specific cytotoxic CD8+
T-cell responses in patients with chronic lymphocytic leukemia.
Leukemia. 24:798–805. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ochi T, Fujiwara H, Suemori K, Azuma T,
Yakushijin Y, Hato T, Kuzushima K and Yasukawa M: Aurora-A kinase:
A novel target of cellular immunotherapy for leukemia. Blood.
113:66–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karthigeyan D, Prasad SB, Shandilya J,
Agrawal S and Kundu TK: Biology of Aurora A kinase: Implications in
cancer manifestation and therapy. Med Res Rev. 31:757–793.
2011.PubMed/NCBI
|
|
13
|
McInnes C and Wyatt MD: PLK1 as an
oncology target: Current status and future potential. Drug Discov
Today. 16:619–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gleixner KV, Ferenc V, Peter B, Gruze A,
Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl
WF, Sillaber C, et al: Polo-like kinase 1 (Plk1) as a novel drug
target in chronic myeloid leukemia: Overriding imatinib resistance
with the Plk1 inhibitor BI 2536. Cancer Res. 70:1513–1523. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang N, Ge G, Meyer R, Sethi S, Basu D,
Pradhan S, Zhao YJ, Li XN, Cai WW, El-Naggar AK, et al:
Overexpression of Separase induces aneuploidy and mammary
tumorigenesis. Proc Natl Acad Sci USA. 105:13033–13038. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meyer R, Fofanov V, Panigrahi A, Merchant
F, Zhang N and Pati D: Overexpression and mislocalization of the
chromosomal segregation protein separase in multiple human cancers.
Clin Cancer Res. 15:2703–2710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rouam S, Moreau T and Broët P: Identifying
common prognostic factors in genomic cancer studies: A novel index
for censored outcomes. BMC Bioinformatics. 11:1502010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Haaß W, Stehle M, Nittka S, Giehl M,
Schrotz-King P, Fabarius A, Hofmann WK and Seifarth W: The
proteolytic activity of separase in BCR-ABL-positive cells is
increased by imatinib. PLoS One. 7:e428632012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamura H, Dan K, Yokose N, Iwakiri R, Ohta
M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, et al:
Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in
peripheral blood in patients with myelodysplastic syndromes. Leuk
Res. 34:986–990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baccarani M, Deininger MW, Rosti G,
Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes
JE, Guilhot F, et al: European LeukemiaNet recommendations for the
management of chronic myeloid leukemia: 2013. Blood. 122:872–884.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Poláková KM, Polívková V, Rulcová J,
Klamová H, Jurcek T, Dvoráková D, Zácková D, Pospísil Z, Mayer J
and Moravcová J: Constant BCR-ABL transcript level ≥=0.1% (IS) in
patients with CML responding to imatinib with complete cytogenetic
remission may indicate mutation analysis. Exp Hematol. 38:20–26.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park DW, Kim SS, Nam MK, Kim GY, Kim J and
Rhim H: Improved recovery of active GST-fusion proteins from
insoluble aggregates: Solubilization and purification conditions
using PKM2 and HtrA2 as model proteins. BMB Rep. 44:279–284. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sehr P, Zumbach K and Pawlita M: A generic
capture ELISA for recombinant proteins fused to glutathione
S-transferase: Validation for HPV serology. J Immunol Methods.
253:153–162. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smahel M: Antigens in chronic myeloid
leukemia: Implications for vaccine development. Cancer Immunol
Immunother. 60:1655–1668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maxwell CA, Rasmussen E, Zhan F, Keats JJ,
Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM,
et al: RHAMM expression and isoform balance predict aggressive
disease and poor survival in multiple myeloma. Blood.
104:1151–1158. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giannopoulos K, Mertens D, Bühler A, Barth
TF, Idler I, Möller P, Kröber A, Greiner J, Chocholska S,
Dmoszyñska A, et al: The candidate immunotherapeutical target, the
receptor for hyaluronic acid-mediated motility, is associated with
proliferation and shows prognostic value in B-cell chronic
lymphocytic leukemia. Leukemia. 23:519–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang J, Ikezoe T, Nishioka C, Udaka K and
Yokoyama A: Bcr-Abl activates AURKA and AURKB in chronic myeloid
leukemia cells via AKT signaling. Int J Cancer. 134:1183–1194.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krusch M and Salih HR: Effects of BCR-ABL
inhibitors on anti-tumor immunity. Curr Med Chem. 18:5174–5184.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith BD, Kasamon YL, Kowalski J, Gocke C,
Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, et
al: K562/GM-CSF immunotherapy reduces tumor burden in chronic
myeloid leukemia patients with residual disease on imatinib
mesylate. Clin Cancer Res. 16:338–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin L, Smith BD, Tsai HL, Yaghi NK, Neela
PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M, et al:
Induction of high-titer IgG antibodies against multiple
leukemia-associated antigens in CML patients with clinical
responses to K562/GVAX immunotherapy. Blood Cancer J. 3:e1452013.
View Article : Google Scholar : PubMed/NCBI
|
